Anupam Rasayan India Ltd Q4 FY25 Earnings Analysis

Published 8 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹13.8K Cr

Price

1,215

Market Cap

₹13.8K Cr

P/E Ratio

81.4

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Anupam Rasayan India Ltd Q4 FY25 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Anupam Rasayan India Ltd share price analysis?

Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847. Investors should review the full earnings analysis for detailed insights.

Is Anupam Rasayan India Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Chemicals & Petrochemicals this season

  • Epigral Ltd (Q4 FY25)

    Epigral Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹4,828, P/E 17.8. AI-pow

  • Clean Science & Technology Ltd (Q4 FY25)

    Clean Science & Technology Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹8,17

  • Jubilant Ingrevia Ltd (Q4 FY25)

    Jubilant Ingrevia Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹11,884, P/E 3

  • Rossari Biotech Ltd (Q4 FY25)

    Rossari Biotech Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹2,908, P/E 19.3